Get Level 2

If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Nominated Adviser Status

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.45    0.12 (3.60%)
Bid:
3.31
Ask:
3.45
Spread: 0.14 (4.23%)
Market Cap: £21.52m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Nominated Adviser Status

1 Nov 2018 13:38

RNS Number : 0704G
Immupharma PLC
01 November 2018
 

 

1 November 2018

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Nominated Adviser Status

 

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

 

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled.

 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496

 

Northland Capital Partners Limited (NOMAD & Joint Broker)David Hignell, Dugald Carlean, Jamie Spotswood, Corporate FinanceRob Rees, Corporate Broking

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0)20 3861 6625

 

 

 

 

+44 (0) 20 3815 8880

 

 

+44 (0) 1483 413500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGGQWGUPRGWG
234567891011
Date   Source Headline
4th Jul 20197:00 amRNSTR-1: notification of major holdings
2nd Jul 20193:33 pmRNSTR-1: notification of major holdings
28th Jun 20197:00 amRNSUpdate on Lupuzor
27th Jun 20191:38 pmRNS2019 Annual General Meeting
26th Jun 20197:00 amRNSSubscription to raise £2.66 million
4th Jun 20197:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20197:00 amRNSFINAL RESULTS
7th May 20197:00 amRNSCorporate Update
1st Apr 20197:00 amRNSUpdate on Nucant Cancer Programme
14th Mar 20197:00 amRNSCorporate Update
26th Feb 20197:00 amRNSTechnology review published-Nature Communications
31st Dec 20187:00 amRNSClinical Development Collaboration with Incanthera
21st Dec 20184:41 pmRNSSecond Price Monitoring Extn
21st Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 20184:35 pmRNSPrice Monitoring Extension
17th Dec 20187:00 amRNSAppointment of Nominated Adviser
7th Dec 20187:00 amRNSUpdate on Corporate Activities
29th Nov 20184:40 pmRNSSecond Price Monitoring Extn
29th Nov 20184:35 pmRNSPrice Monitoring Extension
28th Nov 20184:40 pmRNSSecond Price Monitoring Extn
28th Nov 20184:35 pmRNSPrice Monitoring Extension
23rd Nov 20184:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20184:35 pmRNSPrice Monitoring Extension
21st Nov 20184:40 pmRNSSecond Price Monitoring Extn
21st Nov 20184:35 pmRNSPrice Monitoring Extension
7th Nov 20184:35 pmRNSPrice Monitoring Extension
1st Nov 20181:38 pmRNSNominated Adviser Status
26th Sep 20187:00 amRNSInterim Results
19th Sep 20187:00 amRNSAppointment of Joint Brokers
7th Sep 20187:00 amRNSCorporate Update
10th Jul 20184:40 pmRNSSecond Price Monitoring Extn
10th Jul 20184:35 pmRNSPrice Monitoring Extension
28th Jun 201812:16 pmRNSResult of AGM
14th Jun 20187:00 amRNSResults of CIDP Pre-Clinical Data
6th Jun 20187:00 amRNSNotice of AGM & Posting of Annual Report
29th May 20187:00 amRNSUpdate on Pivotal Phase III Trial of Lupuzor
29th May 20187:00 amRNSFinal Results
24th Apr 201811:59 amRNSHolding(s) in Company
20th Apr 20188:24 amRNSHolding(s) in Company
19th Apr 20188:05 amRNSHolding(s) in Company
17th Apr 20187:00 amRNSTopline results of Lupuzor Pivotal Phase III Trial
28th Mar 20187:00 amRNSAppointment of Joint Broker
23rd Mar 20187:00 amRNSLupuzor Pivotal Phase III Study Update
5th Mar 20184:13 pmRNSAIM Notice (17)
15th Feb 20187:00 amRNSLondon Investor Evening
9th Feb 20182:00 pmRNSHolding(s) in Company
7th Feb 20189:35 amRNSHolding(s) in Company
5th Feb 20187:00 amRNSHolding(s) in Company
31st Jan 201810:23 amRNSHolding(s) in Company
24th Jan 20187:00 amRNSSuccessful Placing to Raise £10 Million
234567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
HRN
Hornby
LSE
0.00%
PTAL
PetroTal
LSE
-3.13%
EPO
Earthport
LSE
0.00%
TFIF
Twentyfour Inc
LSE
0.00%
PGIT
PGIT.L
LSE
0.00%
Trending
ORCP
Oracle Power
LSE
-15.00%
QHE
Quantum Helium
LSE
10,145.90%
GGP
Greatland Resources
LSE
1.17%
HEX
Helix Exploration
LSE
-6.73%
MPAL
Medpal AI
LSE
-10.00%